DK1781604T3 - Bis(thio-hydrazid-amid)-salte til behandling af cancere - Google Patents

Bis(thio-hydrazid-amid)-salte til behandling af cancere

Info

Publication number
DK1781604T3
DK1781604T3 DK05762347.2T DK05762347T DK1781604T3 DK 1781604 T3 DK1781604 T3 DK 1781604T3 DK 05762347 T DK05762347 T DK 05762347T DK 1781604 T3 DK1781604 T3 DK 1781604T3
Authority
DK
Denmark
Prior art keywords
amid
hydrazide
thio
cancers
bis
Prior art date
Application number
DK05762347.2T
Other languages
Danish (da)
English (en)
Inventor
Takayo Inoue
Shoujun Chen
Farid Vaghefi
Guiqing Liang
Keizo Koya
Lijun Sun
Noriaki Tatsuta
Zhi-Qiang Xia
Elena Kostik
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Application granted granted Critical
Publication of DK1781604T3 publication Critical patent/DK1781604T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/38Amides of thiocarboxylic acids
    • C07C327/56Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DK05762347.2T 2004-06-23 2005-06-20 Bis(thio-hydrazid-amid)-salte til behandling af cancere DK1781604T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58259604P 2004-06-23 2004-06-23
US68136805P 2005-05-16 2005-05-16
PCT/US2005/021642 WO2006009940A1 (en) 2004-06-23 2005-06-20 Bis(thio-hydrazide amide) salts for treatment of cancers

Publications (1)

Publication Number Publication Date
DK1781604T3 true DK1781604T3 (da) 2013-09-16

Family

ID=34993190

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05762347.2T DK1781604T3 (da) 2004-06-23 2005-06-20 Bis(thio-hydrazid-amid)-salte til behandling af cancere

Country Status (21)

Country Link
US (5) US7385084B2 (https=)
EP (2) EP1781604B1 (https=)
JP (1) JP5362986B2 (https=)
KR (1) KR101313027B1 (https=)
CN (1) CN1993318B (https=)
AU (1) AU2005265202B2 (https=)
BR (1) BRPI0512526A (https=)
CA (1) CA2570698C (https=)
DK (1) DK1781604T3 (https=)
ES (1) ES2430373T3 (https=)
HR (1) HRP20131023T1 (https=)
IL (1) IL179632A (https=)
ME (1) ME01644B (https=)
NO (1) NO20070378L (https=)
NZ (1) NZ552159A (https=)
PL (1) PL1781604T3 (https=)
PT (1) PT1781604E (https=)
RS (1) RS52999B (https=)
RU (2) RU2406722C2 (https=)
TW (1) TWI389684B (https=)
WO (1) WO2006009940A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
CN1993318B (zh) * 2004-06-23 2012-10-03 Synta医药公司 用于治疗癌症的双(硫代-酰肼酰胺)盐
JP5204489B2 (ja) 2004-11-19 2013-06-05 シンタ ファーマスーティカルズ コーポレイション Hsp70発現を増加するためのビス(チオ‐ヒドラジドアミド)
EP1871350A1 (en) * 2005-04-15 2008-01-02 Synta Pharmaceuticals Corporation Methods of increasing natural killer cell activity for therapy
WO2006113695A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
KR20080008399A (ko) * 2005-05-16 2008-01-23 신타 파마슈티칼스 코프. 비스(티오-히드라지드 아미드) 염의 합성 방법
KR20080035642A (ko) * 2005-08-16 2008-04-23 신타 파마슈티칼스 코프. 비스(티오-히드라지드 아미드) 제제
US20100310587A1 (en) * 2005-08-29 2010-12-09 Academia Sinica Immunomodulatory compositions
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
TWI440632B (zh) * 2006-08-21 2014-06-11 Synta Pharmaceuticals Corp 用於治療增生性疾病的化合物
EP2061451A2 (en) * 2006-08-21 2009-05-27 Synta Pharmaceuticals Corporation Bis(thiohydrazide amides) for treating melanoma
TW200817348A (en) * 2006-08-21 2008-04-16 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
WO2008024301A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
US20100068174A1 (en) * 2006-08-21 2010-03-18 Synta Pharmaceuticals Corp. Combination with bis (thiohydrazide amides) for treating cancer
JP2010502616A (ja) 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス(チオヒドラジドアミド)の組み合わせ
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
US7645904B2 (en) 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
WO2009064374A2 (en) * 2007-11-09 2009-05-22 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
WO2009105257A1 (en) 2008-02-21 2009-08-27 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009123704A2 (en) * 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
CN102256937B (zh) * 2008-10-22 2014-12-17 辛塔医药品有限公司 双[硫代酰肼酰胺]化合物的过渡金属络合物
MX2011004114A (es) 2008-10-22 2011-08-15 Synta Pharmaceuticals Corp Complejos de metales de transicion de un compuesto bis (tiohidrazida amida).
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
JP5631327B2 (ja) 2008-12-01 2014-11-26 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
RU2400471C1 (ru) * 2009-04-30 2010-09-27 Учреждение Российской академии наук Институт органической химии им. Н.Д. Зелинского РАН (ИОХ РАН) N-замещенные производные тиогидразидов оксаминовых кислот, способ их получения и их использование
US8822532B2 (en) * 2009-12-04 2014-09-02 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
EP2560627A1 (en) 2010-04-20 2013-02-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide]compounds such as elesclomol for treating cancers
WO2012068491A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
US20140329892A1 (en) * 2011-11-10 2014-11-06 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
US20130149392A1 (en) 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
US20150057357A1 (en) * 2012-01-05 2015-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers
US12610818B2 (en) 2023-02-07 2026-04-21 Semiconductor Components Industries, Llc Single switch direct cooling assemblies and related methods

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) * 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (https=) 1973-12-17 1975-07-21
US4822777A (en) * 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のn−(場合により置換された)−n′−置換−n,n′−ジ置換ヒドラジン
US6013836A (en) * 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
JPH10501215A (ja) 1994-06-03 1998-02-03 ビーエーエスエフ アクチェンゲゼルシャフト カルバモイルカルボン酸ヒドラジド
CA2232727C (en) * 1995-09-22 2002-03-26 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US5739686A (en) * 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) * 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
RU2191015C2 (ru) * 1999-11-05 2002-10-20 Общество с ограниченной ответственностью "Центр бифункциональных иммуномодуляторов" Динатриевая соль n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5h-пиримидинсульфон)-n'- изоникотиноилгидразида, проявляющая антимикробную и иммунотропную активность, и лекарственное средство на ее основе
US6322303B1 (en) * 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) * 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) * 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
JP2004532187A (ja) * 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
CA2445967A1 (en) * 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
EP1387678A1 (en) 2001-05-03 2004-02-11 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) * 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
US6924312B2 (en) * 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
BR0214553A (pt) * 2001-11-28 2004-10-13 Sod Conseils Rech Applic Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 p38/JTV-1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
KR100486693B1 (ko) * 2003-03-17 2005-05-03 삼성전자주식회사 금속 매립 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
KR100544347B1 (ko) * 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
WO2005097758A1 (en) 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
US7011923B2 (en) * 2004-04-07 2006-03-14 International Business Machines Corporation Negative photoresist and method of using thereof
CN1993318B (zh) * 2004-06-23 2012-10-03 Synta医药公司 用于治疗癌症的双(硫代-酰肼酰胺)盐
WO2006033913A2 (en) 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
JP5204489B2 (ja) 2004-11-19 2013-06-05 シンタ ファーマスーティカルズ コーポレイション Hsp70発現を増加するためのビス(チオ‐ヒドラジドアミド)
NZ560712A (en) 2005-02-17 2010-12-24 Synta Pharmaceuticals Corp (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
WO2006113695A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
EP1871350A1 (en) 2005-04-15 2008-01-02 Synta Pharmaceuticals Corporation Methods of increasing natural killer cell activity for therapy
KR20080008399A (ko) * 2005-05-16 2008-01-23 신타 파마슈티칼스 코프. 비스(티오-히드라지드 아미드) 염의 합성 방법
KR20080035642A (ko) 2005-08-16 2008-04-23 신타 파마슈티칼스 코프. 비스(티오-히드라지드 아미드) 제제
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20100068174A1 (en) 2006-08-21 2010-03-18 Synta Pharmaceuticals Corp. Combination with bis (thiohydrazide amides) for treating cancer
WO2008024301A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
US8497272B2 (en) 2006-08-21 2013-07-30 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
EP2061451A2 (en) 2006-08-21 2009-05-27 Synta Pharmaceuticals Corporation Bis(thiohydrazide amides) for treating melanoma
TWI440632B (zh) 2006-08-21 2014-06-11 Synta Pharmaceuticals Corp 用於治療增生性疾病的化合物
JP2010502616A (ja) 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス(チオヒドラジドアミド)の組み合わせ
AU2007294969A1 (en) 2006-09-11 2008-03-20 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) formulation
AU2007294752A1 (en) 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
US7645904B2 (en) 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
US20090093538A1 (en) * 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
US8093425B2 (en) * 2007-04-30 2012-01-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009020631A2 (en) 2007-08-07 2009-02-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009064374A2 (en) 2007-11-09 2009-05-22 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8637704B2 (en) 2007-11-28 2014-01-28 Synta Pharmaceuticals Corp. Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide)
JP5091056B2 (ja) 2008-08-28 2012-12-05 三甲株式会社 密閉容器の蓋部シール構造

Also Published As

Publication number Publication date
TWI389684B (zh) 2013-03-21
HK1104526A1 (en) 2008-01-18
CN1993318A (zh) 2007-07-04
EP1781604B1 (en) 2013-08-07
NO20070378L (no) 2007-03-16
RU2406722C2 (ru) 2010-12-20
CA2570698A1 (en) 2006-01-26
US7579503B2 (en) 2009-08-25
PT1781604E (pt) 2013-10-15
JP5362986B2 (ja) 2013-12-11
BRPI0512526A (pt) 2008-03-11
JP2008504264A (ja) 2008-02-14
US8461208B2 (en) 2013-06-11
TW200612895A (en) 2006-05-01
US20120035266A1 (en) 2012-02-09
US20080269340A1 (en) 2008-10-30
ES2430373T3 (es) 2013-11-20
US20060135595A1 (en) 2006-06-22
EP2305642A2 (en) 2011-04-06
RU2010145056A (ru) 2012-05-20
IL179632A0 (en) 2007-05-15
US7385084B2 (en) 2008-06-10
NZ552159A (en) 2009-12-24
EP2305642A3 (en) 2011-12-14
US8048925B2 (en) 2011-11-01
US7795313B2 (en) 2010-09-14
KR101313027B1 (ko) 2013-10-02
IL179632A (en) 2012-08-30
ME01644B (me) 2014-09-20
PL1781604T3 (pl) 2014-01-31
HRP20131023T1 (hr) 2013-12-06
KR20070029259A (ko) 2007-03-13
AU2005265202B2 (en) 2009-07-23
US20090281172A1 (en) 2009-11-12
EP1781604A1 (en) 2007-05-09
WO2006009940A1 (en) 2006-01-26
CN1993318B (zh) 2012-10-03
US20100324143A1 (en) 2010-12-23
CA2570698C (en) 2013-11-19
RU2007101898A (ru) 2008-07-27
RS52999B (sr) 2014-02-28
AU2005265202A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
DK1781604T3 (da) Bis(thio-hydrazid-amid)-salte til behandling af cancere
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
DK1778618T3 (da) Syntese af triethylentetraminer
DK1959981T3 (da) Anti-connexin 43 forbindelser til behandling af kroniske sår
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK1755671T3 (da) Terapi af platinresistent cancer
DK2423325T3 (da) Fremgangsmåde til fremstilling af biblioteker af template-polynukleotider
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1830850T3 (da) Quinolin-derivater til behandling af latent tuberkulose
DK1877232T3 (da) Fremgangsmåde til behandling af træoverflader
DK1948180T3 (da) Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
DK2377869T3 (da) Syntese af Bortezomib
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1948693T3 (da) Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK1863833T3 (da) Fremgangsmåde til fremstilling af makrocykliske forbindelser
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
ATE435198T1 (de) Orthosubstituierte aryl- oder heteroarylamidverbindungen
DK3470535T3 (da) Forudsigelse af sandsynlighed for tilbagevenden af cancer
DK1960370T3 (da) Pyridazinonderivater til tumorbehandling
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1812895T3 (da) Stofkilde
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet